Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients
Status:
Completed
Trial end date:
2021-04-05
Target enrollment:
Participant gender:
Summary
A total of 278 patients are planned.
All patients will be in an early-stage of COVID-19. They must be adults and hospitalized.
In this study, all participating patients will receive the standard treatment provided
according to the current treatment protocols for coronavirus disease. In addition to this
treatment, each patient will be randomly assigned to receive additional treatment with
convalescent plasma transfusion (CP; blood plasma from patients who have been cured of
coronavirus), or continue with standard treatment but without adding transfusion.
50% of the chances of additional treatment with CP, and 50% of the chances of receiving only
the standard treatment for coronavirus.
The duration of the study shall be one month from the assignment of the treatment.
The patient and the doctor will know the treatment assigned.